EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis



Ibandronate: the first once-monthly oral bisphosphonate for treatment of postmenopausal osteoporosis



Therapeutics and Clinical Risk Management 2(1): 3-18



Osteoporosis is a major healthcare problem that continues growing as the population ages. Sufferers become increasingly susceptible to fractures, which compromise physical and emotional health and increase healthcare costs. Bisphosphonates are the most widely used medicines for the treatment and prevention of postmenopausal osteoporosis. However, therapeutic adherence is suboptimal, meaning that outcomes demonstrated in clinical trials are not realized in the real world. It is anticipated that reducing dosing frequency may facilitate medication intake and thereby improve adherence. Ibandronate is a potent nitrogen-containing bisphosphonate specifically developed for administration with long dose-free intervals. The comprehensive ibandronate preclinical development program has demonstrated dose-dependent improvements or preservation of bone quality and strength. The feasibility of intermittent dosing using the same total dose level as continuous dosing was also confirmed. In postmenopausal osteoporosis, once-monthly oral ibandronate has been shown to be therapeutically equivalent and even superior to daily oral ibandronate, which has demonstrated antifracture efficacy for vertebral and nonvertebral fractures, bone mineral density gains at the spine and hip, and reduction in bone resorption to premenopausal levels. Once-monthly oral ibandronate is also associated with excellent safety and tolerability, and promises to further improve therapeutic adherence to bisphosphonate treatment, thereby enhancing therapeutic outcomes.

(PDF emailed within 1 workday: $29.90)

Accession: 053653040

Download citation: RISBibTeXText

PMID: 18360577



Related references

Update on monthly oral bisphosphonate therapy for the treatment of osteoporosis: focus on ibandronate 150 mg and risedronate 150 mg. Current Medical Research and Opinion 25(12): 2951-2960, 2010

Treatment preference for monthly oral ibandronate and weekly oral alendronate in women with postmenopausal osteoporosis: A randomized, crossover study (BALTO II). Joint, Bone, Spine 75(3): 303-310, 2007

Ibandronate: A New Oral Bisphosphonate for Postmenopausal Osteoporosis. Consultant Pharmacist 20(12): 1036-1055, 2005

Ibandronate: a new oral bisphosphonate for postmenopausal osteoporosis. Consultant Pharmacist 20(12): 1036-1055, 2006

Efficacy and tolerability of once-monthly oral ibandronate (150 mg) and once-weekly oral alendronate (70 mg): additional results from the Monthly Oral Therapy With Ibandronate For Osteoporosis Intervention (MOTION) study. Clinical Therapeutics 31(4): 751-761, 2009

Once-monthly oral ibandronate in postmenopausal osteoporosis: translation and updated review. Clinical Therapeutics 31(7): 1497-1510, 2009

Denosumab significantly increases bone mineral density and reduces bone turnover compared with monthly oral ibandronate and risedronate in postmenopausal women who remained at higher risk for fracture despite previous suboptimal treatment with an oral bisphosphonate. Osteoporosis International 25(7): 1953-1961, 2015

Clinical efficacy and safety of monthly oral ibandronate 100 mg versus monthly intravenous ibandronate 1 mg in Japanese patients with primary osteoporosis. Osteoporosis International 26(11): 2685-2693, 2016

The BALTO II study: Patient preference for once-monthly oral ibandronate and weekly oral alendronate in postmenopausal osteoporosis. 2006

Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. Journal of Bone and Mineral Research 20(8): 1315-1322, 2005

Similar improvements in hip bone mineral density with monthly oral ibandronate (150mg) versus weekly oral alendronate (70mg) in postmenopausal osteoporosis. 2007

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Annals of the Rheumatic Diseases 65(5): 654-661, 2005

Response to once-monthly and daily oral ibandronate in women with postmenopausal osteoporosis: 2-year findings from mobile. 2006

Efficacy and tolerability of once-monthly oral ibandronate in postmenopausal osteoporosis: 2 year results from the MOBILE study. Yearbook of Endocrinology 2007: 331-333, 2007

Once-monthly oral ibandronate improves biomechanical determinants of bone strength in women with postmenopausal osteoporosis. Journal of Clinical Endocrinology and Metabolism 94(1): 171-180, 2008